JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Search

Editas Medicine Inc

Open

BrancheGesundheitswesen

3.07 2.68

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.94

Max

3.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

23M

-53M

Verkäufe

-1.1M

3.6M

Gewinnspanne

-1,487.842

Angestellte

246

EBITDA

23M

-49M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+28.9% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

108M

292M

Vorheriger Eröffnungskurs

0.39

Vorheriger Schlusskurs

3.07

Nachrichtenstimmung

By Acuity

50%

50%

168 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Okt. 2025, 23:32 UTC

Heiße Aktien

Stocks to Watch: Amazon, Reddit, SPS Commerce

30. Okt. 2025, 23:02 UTC

Ergebnisse

AIA Group 3Q Value of New Business Grew

30. Okt. 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30. Okt. 2025, 23:00 UTC

Ergebnisse

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30. Okt. 2025, 22:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

30. Okt. 2025, 22:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30. Okt. 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30. Okt. 2025, 22:35 UTC

Ergebnisse

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30. Okt. 2025, 22:35 UTC

Ergebnisse

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30. Okt. 2025, 22:31 UTC

Ergebnisse

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30. Okt. 2025, 22:29 UTC

Ergebnisse

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30. Okt. 2025, 22:27 UTC

Ergebnisse

Minas Buenaventura 3Q EPS 66c >BVN

30. Okt. 2025, 22:27 UTC

Ergebnisse

Minas Buenaventura 3Q Rev $431M >BVN

30. Okt. 2025, 22:27 UTC

Ergebnisse

Minas Buenaventura 3Q Net $179M >BVN

30. Okt. 2025, 22:16 UTC

Market Talk
Ergebnisse

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30. Okt. 2025, 22:14 UTC

Ergebnisse

Review & Preview: A Tech Earnings Storm -- Barrons.com

30. Okt. 2025, 22:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30. Okt. 2025, 21:39 UTC

Ergebnisse

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30. Okt. 2025, 21:26 UTC

Ergebnisse

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30. Okt. 2025, 21:14 UTC

Market Talk
Ergebnisse

Apple Sees Record Quarterly Services Revenue -- Market Talk

30. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

30. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30. Okt. 2025, 21:04 UTC

Ergebnisse

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30. Okt. 2025, 21:03 UTC

Ergebnisse

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30. Okt. 2025, 21:03 UTC

Ergebnisse

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold Skouries on Track for 1Q of 2026

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q Adj EPS 41c >EGO

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q Rev $434.7M >EGO

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q Net $56M >EGO

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q EPS 27c >EGO

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

28.9% Vorteil

12-Monats-Prognose

Durchschnitt 3.88 USD  28.9%

Hoch 6 USD

Tief 1 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

5

Buy

5

Halten

2

Sell

Technischer Score

By Trading Central

1.33 / 1.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

No Evidence

Stimmung

By Acuity

168 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat